NCT03369223: A reported trial by Bristol-Myers Squibb
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03369223 |
|---|---|
| Title | A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 6, 2017 |
| Completion date | Nov. 7, 2024 |
| Required reporting date | Nov. 7, 2025, midnight |
| Actual reporting date | Nov. 6, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |